Head to head
BPC-157 against Zinc-L-carnosine
Two compounds sold for the gut lining with very different regulatory histories. Zinc-L-carnosine is an approved prescription gastric medicine in Japan with a randomised phase 3 in radiotherapy-induced swallowing difficulty; BPC-157 is not approved anywhere.
Column A
BPC-157Body Protection Compound 157
A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.
Column B
Zinc-L-carnosineZinc-L-carnosine (polaprezinc), zinc and carnosine chelate
A zinc and dipeptide chelate approved as a gastric drug in Japan, with a randomised phase 3 showing it prevented radiotherapy-induced swallowing difficulty in breast cancer patients.
Side by side, on the facts we can check
| Attribute | BPC-157 | Zinc-L-carnosine |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action | Not an FDA-approved drug. Sold as a dietary supplement in the United States. Approved as a prescription gastric medicine in Japan, where it has been marketed since 1994. |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | Not meaningfully described as a chelate, because its intended action is local adhesion to mucosa and local zinc release rather than systemic exposure. |
| Molecular weight | 1,419.5 Da | Roughly 289 Da for the zinc and L-carnosine complex. |
| Mechanism | In animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days. | A one-to-one chelate of zinc and L-carnosine. The chelate adheres preferentially to ulcerated and inflamed mucosal surfaces, where it dissociates and releases zinc locally at higher concentration than systemic zinc dosing would achieve. Zinc contributes to epithelial repair, membrane stabilisation and antioxidant defence through metallothionein induction, and carnosine has direct antioxidant and metal-chelating activity. In cell and animal work it accelerates epithelial migration and restitution, and it raises heat shock protein expression. Note that its actions are largely local to mucosa, which is why the evidence concerns gut and mucosal injury rather than systemic outcomes. |
| Human studies cited | 5 | 1 |
| Legal status, US | Not approved; research use only | Sold as a supplement |
Frequently asked questions
What is the difference between BPC-157 and Zinc-L-carnosine?
BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Zinc-L-carnosine: A zinc and dipeptide chelate approved as a gastric drug in Japan, with a randomised phase 3 showing it prevented radiotherapy-induced swallowing difficulty in breast cancer patients.
Which has stronger research evidence, BPC-157 or Zinc-L-carnosine?
This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 1 of 1 for Zinc-L-carnosine. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are BPC-157 and Zinc-L-carnosine FDA-approved?
BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Zinc-L-carnosine: Not an FDA-approved drug. Sold as a dietary supplement in the United States. Approved as a prescription gastric medicine in Japan, where it has been marketed since 1994..
Related posts
Blog articles that cover BPC-157 or Zinc-L-carnosine, newest first.
- Healing & Recovery / Sep 8, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 8, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.